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Abstract
Introduction Overexpression of the ERBB2  oncogene is
observed in about 20% of human breast tumors and is the
consequence of increased transcription rates frequently
associated with gene amplification. Several studies have shown
a link between activator protein 2 (AP-2) transcription factors
and  ERBB2  gene expression in breast cancer cell lines.
Moreover, the Yin Yang 1 (YY1) transcription factor has been
shown to stimulate AP-2 transcriptional activity on the ERBB2
promoter in vitro. In this report, we examined the relationships
between ERBB2, AP-2α, and YY1 both in breast cancer tissue
specimens and in a mammary cancer cell line.
Methods ERBB2, AP-2α, and YY1 protein levels were analyzed
by immunohistochemistry in a panel of 55 primary breast tumors.
ERBB2  gene amplification status was determined by
fluorescent in situ hybridization. Correlations were evaluated by
a χ2 test at a p value of less than 0.05. The functional role of AP-
2α and YY1 on ERBB2 gene expression was analyzed by small
interfering RNA (siRNA) transfection in the BT-474 mammary
cancer cell line followed by real-time reverse transcription-
polymerase chain reaction and Western blotting.
Results We observed a statistically significant correlation
between ERBB2 and AP-2α levels in the tumors (p < 0.01).
Moreover, associations were found between ERBB2 protein
level and the combined high expression of AP-2α and YY1 (p <
0.02) as well as between the expression of AP-2α and YY1 (p
< 0.001). Furthermore, the levels of both AP-2α and YY1
proteins were inversely correlated to ERBB2 gene amplification
status in the tumors (p < 0.01). Transfection of siRNAs targeting
AP-2α and AP-2γ mRNAs in the BT-474 breast cancer cell line
repressed the expression of the endogenous ERBB2 gene at
both the mRNA and protein levels. Moreover, the additional
transfection of an siRNA directed against the YY1 transcript
further reduced the ERBB2 protein level, suggesting that AP-2
and YY1 transcription factors cooperate to stimulate the
transcription of the ERBB2 gene.
Conclusion This study highlights the role of both AP-2α and
YY1 transcription factors in ERBB2 oncogene overexpression
in breast tumors. Our results also suggest that high ERBB2
expression may result either from gene amplification or from
increased transcription factor levels.
Introduction
The ERBB2 oncogene (also known as HER2) belongs to the
epidermal growth factor receptor gene family and encodes a
185-kDa receptor tyrosine kinase [1]. The ERBB2 gene is
overexpressed in several human tumors, mostly in breast and
ovary carcinomas, where the overexpression is a marker of
poor prognosis [2]. Moreover, ERBB2 gene overexpression is
able to transform cells in culture and to induce mammary
tumors in transgenic mice [3]. ERBB2 gene-overexpressing
tumors are more aggressive due to increased invasive,
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metastatic, and angiogenic phenotypes [4]. Therefore, eluci-
dating the mechanisms leading to ERBB2 gene overexpres-
sion is an important step in understanding the pathogenesis of
a particularly aggressive subset of breast tumors.
Several laboratories have undertaken the study of the mecha-
nisms leading to the accumulation of high levels of ERBB2
transcript and corresponding protein in breast cancer cells.
First, the overexpression of the ERBB2 gene has been shown
to be partly explained by gene amplification [5]. However, in
breast cancer cell lines, regardless of whether the gene is
amplified, there is a higher ERBB2 mRNA level per gene copy
in overexpressing tumor cells compared with cells with a low
ERBB2 expression [6,7]. In addition, we and others have dem-
onstrated that ERBB2  overexpression is due to increased
transcription rates and not to the stabilization of the mRNA
[6,8]. Further experiments, therefore, were needed to identify
the activating sequences in the ERBB2 promoter, and the
molecules that bind them, such as the activator protein 2 (AP-
2) transcription factors.
The AP-2 family currently includes five related 50-kDa pro-
teins: AP-2α, AP-2β, AP-2γ [9], AP-2δ [10], and AP-2ε [11].
Several in vitro and in vivo sets of data have demonstrated a
connection between AP-2 transcription factors and ERBB2
expression. First, four AP-2 binding sequences were identified
in the ERBB2 promoter [12-15]. Then, we reported the in vivo
binding of AP-2 proteins to these sites on the endogenous
ERBB2 promoter by chromatin immunoprecipitation (ChIP)
experiments [13,16]. Moreover, in vitro results of transfection
experiments have shown that AP-2 factors contribute signifi-
cantly to the activity of the ERBB2 promoter [9,12-16]. In par-
ticular, expression of a dominant negative AP-2 protein in
mammary cancer cells was shown to result in the inhibition of
the transcription from a reporter vector bearing a 6-kb frag-
ment of the ERBB2 promoter [13]. Finally, AP-2 transcription
factors have been shown to be highly expressed in breast can-
cer cell lines overexpressing ERBB2 [9,14].
AP-2 factors modulate transcription through interactions with
several nuclear factors (for example, PARP [17], PC4 [18],
CITED2 [19], CITED4 [20], and p300 [21]). Recently, we
identified Yin Yang 1 (YY1) as a new cofactor stimulating AP-
2 transcriptional activity [16]. YY1 is a multifunctional tran-
scription factor that modulates the expression of a wide variety
of genes [22]. It can act as a transcriptional activator or repres-
sor, depending on the context of its binding site within a par-
ticular promoter [23] and on other cell type-specific factors
[24]. A wide variety of proteins are able to bind to YY1, indi-
cating that protein-protein interactions are important for its
activity. Among these proteins, YY1 interacts with AP-2α
through a domain highly conserved in AP-2γ [25]. Moreover,
YY1 enhances AP-2α, AP-2β, and AP-2γ transcriptional activ-
ity on the ERBB2 promoter in breast cancer cells [16]. ChIP
experiments also showed that the YY1 protein is recruited on
the endogenous ERBB2 promoter only when a member of the
AP-2 protein family is present [16].
The aim of this study was to characterize better the relation-
ship between the overexpression of ERBB2 oncogene and
AP-2α transcription factor in primary breast tumors and to
determine whether the expression level of the YY1 cofactor
could play a role in the association between the expression of
AP-2α and ERBB2. In this study, we first demonstrated that
the expression of these proteins is positively correlated in
breast cancer tissues. These results were further associated
with ERBB2 gene amplification status and then corroborated
by a functional analysis using small interfering RNA (siRNA)
transfected in a mammary cancer cell line. Altogether, our data
indicate that ERBB2 gene amplification or increased levels of
transcription factors may lead to a pathologically high level of
ERBB2 transcript and protein in breast cancer.
Materials and methods
Tissue samples
A series of 55 primary tumors from breast cancer patients
diagnosed between 2002 and 2004 at the University Hospital
of Liege, Belgium, was analyzed. The mean age of the patients
was 61.9 years and the median was 59.0 years (range: 38.0
to 88.0 years). The clinicopathological data of the patients are
summarized in Table 1. The tumor samples were fixed in 10%
buffered formalin and embedded in paraffin. The histological
diagnosis was confirmed by reviewing the original sections of
the primary tumors. All of the tumors were simultaneously eval-
uated for histological type and grade by senior pathologists.
The most representative blocks were selected and cut into
new 5-μm-thick sections for immunohistochemical analyses.
The study was approved by the local ethics committee at the
Liege University Hospital.
Immunohistochemistry
Sections of breast biopsy specimens underwent immunoper-
oxidase staining using antibodies directed against AP-2α
(1:100) (#39001; Active Motif, Carlsbad, CA, USA), against
YY1 (1:50) (H-10; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), or against ERBB2 (1:250) (A0485; Dako A/
S, Glostrup, Denmark). The sections were deparaffinized in
xylene and rehydrated in methanol. Endogenous peroxidases
were blocked by 5% H2O2  treatment. For better antigen
retrieval, the samples were boiled either in a microwave oven
for 3 × 5 minutes in citrate buffer (AP-2α and YY1) or in a
water bath at 99°C in EDTA (ethylenediaminetetraacetic acid)
buffer for 40 minutes (ERBB2). Samples were then washed
with phosphate-buffered saline-Tween (pH 7.2; 1.5%) and
incubated with the primary antibody at room temperature for
30 minutes (AP-2α and YY1) or 1 hour (ERBB2). After wash-
ings, the revelation was performed with the use of appropriate
secondary antibodies and the LSAB2 system (AP-2α and
Y Y 1 ;  D a k o  A / S )  o r  t h e  E n V i s i o n  k i t  ( E R B B 2 ;  D a k o  A / S )
according to the supplier's recommendations. Immunoreactiv-Available online http://breast-cancer-research.com/content/10/1/R9
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Table 1
Clinicopathological data of the patients and their relationships with ERBB2 expression
Characteristic n (Percentage) ERBB2 expression (percentage) P value
(0/1+/2+) (3+)
Number of patients 55 (100) 40 (73) 15 (27)
Tumor size NS
T1 20 (36) 16 (80) 4 (20)
T2 29 (53) 20 (69) 9 (31)
T3 6 (11) 4 (67) 2 (33)
Lymph node status NS
Negative 33 (60) 24 (73) 9 (27)
Positive 22 (40) 16 (73) 6 (27)
Grade
Not determined 3 (5) /
I 12 (22) 29 (83) 6 (17) 0.060
II 23 (42)
III 17 (31) 10 (59) 7 (41)
Histological type NS
Ductal 40 (73) 28 (70) 12 (30)
Lobular 7 (13) 5 (71) 2 (29)
Other 8 (14) 7 (87) 1 (13)
ER status 0.035
Positive 42 (76) 34 (81) 8 (19)
Negative 13 (24) 6 (46) 7 (54)
PR status 0.022
Positive 32 (58) 27 (84) 5 (16)
Negative 23 (42) 13 (57) 10 (43)
Menopausal status NS
Premenopausal 9 (16) 8 (89) 1 (11)
Postmenopausal 46 (84) 32 (70) 14 (30)
Ki67 0.018
Low 29 (53) 25 (86) 4 (14)
High 26 (47) 15 (58) 11 (42)Breast Cancer Research    Vol 10 No 1    Allouche et al.
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ity was visualized by a treatment with diaminobenzidine
(Sigma-Aldrich, St. Louis, MO, USA), and the slides were
counterstained with Mayer's hematoxylin.
For statistical analyses of AP-2α and YY1 immunoreactivity,
the percentage distribution of stained tumor cell nuclei in the
sample was divided into low (<80%) or high (≥ 80%) expres-
sion groups according to Pellikainen and colleagues [26].
ERBB2 scoring was performed according to the recently pro-
posed guidelines from the American Society of Clinical Oncol-
ogy (ASCO) and the College of American Pathologists (CAP)
[27]. Pathological ERBB2 overexpression (3+) was detected
in 27% of tumors. There was a significant statistical associa-
tion between ERBB2 overexpression and Ki67 immunostain-
ing, and an inverse relationship was demonstrated with
estrogen receptor and progesterone receptor status (Table 1).
Furthermore, a trend toward a direct link between ERBB2
overexpression and both p53 expression and histological
grade III was observed.
Fluorescent in situ hybridization
Fluorescent in situ hybridization (FISH) was performed with
the INFORM HER-2/neu probe (approved by the U.S. Food
and Drug Administration) and the BenchMark XT automated
system (Ventana Medical Systems, Inc., Tucson, AZ, USA)
according to the supplier's recommendations. A minimum of
50 cell nuclei were counted, and gene amplification was con-
sidered as present when an average of more than six ERBB2
gene copies per cell was observed [27].
Statistics
The statistical analyses were carried out with a χ2 test for cat-
egorical variables at a p value of less than 0.05 for significance
by using Statistica software (StatSoft, Inc., Tulsa, OK, USA).
Cell line
The BT-474 human mammary carcinoma cells were pur-
chased from the American Type Culture Collection (Manas-
sas, VA, USA) and cultured in the RPMI 1640 medium
supplemented with 10% (vol/vol) fetal bovine serum, 2 mM
glutamine, and 100 μg/mL penicillin/streptomycin (all from
Cambrex Bio Science Verviers S.p.r.l., Verviers, Belgium).
Small interfering RNAs
Cells were transfected (a) on days 0 and 2 by 150 nM siRNA
directed against AP-2α and/or AP-2γ transcripts as indicated
or (b) on day 0 by 30 nM siRNA against YY1, or 100 nM com-
bined siRNAs against AP-2α and AP-2γ transcripts, or both as
indicated. As control, cells were transfected by either an
siRNA against luciferase mRNA [28] or a negative control
siRNA OR-0030-neg05 from Eurogentec S.A. (Seraing, Bel-
gium). Total RNA was extracted after 2 to 4 days of treatment.
Real-time reverse transcription-polymerase chain reaction
(RT-PCR) for AP-2α, AP-2γ, ERBB2, and β2-microglobulin
(standard gene) transcripts were performed on 1 μg of total
extracted RNA. The standardized transcript levels were
reported to the values obtained in cells transfected with the
control siRNA. The RT-PCR analysis was performed on an ABI
Prism 7000 apparatus (Applied Biosystems, Foster City, CA,
USA) using standard protocol. Western blot analysis was per-
formed on proteins extracted after 1 or 3 days of treatment as
indicated. The antibodies used for Western blot were 3B5 for
AP-2α, 6E4/4 for AP-2γ, H-10 for YY1, and C-19 for Ku70 (all
purchased from Santa Cruz Biotechnology, Inc.) and a rabbit
antibody for ERBB2 (06–562; Upstate, now part of Millipore
Corporation, Billerica, MA, USA). The sequences of the siR-
NAs and the RT-PCR primers (all purchased from Eurogentec
S.A.) are presented in Table 2.
Results
Combined high AP-2a and YY1 levels are associated 
with expression of ERBB2 in breast cancer tissue 
samples
We first detected levels of ERBB2, AP-2α, and YY1 proteins
by immunohistochemistry (IHC) in tumor specimens from 55
cases of breast carcinomas (Tables 1 and 3). Representative
examples of the staining patterns obtained for ERBB2 recep-
tor and the transcription factors AP-2α and YY1 are shown in
Figure 1. The AP-2α and YY1 proteins were detected mainly
in the nuclear compartment, while cytoplasmic staining was
rare and weak (Figure 1a–d). We scored the AP-2α and YY1
levels as low or high regarding the percentage of stained
nuclei according to Pellikainen and colleagues [26] (Figure 1).
High AP-2α and YY1 protein levels were seen in 42% and
45% of breast carcinomas, respectively. For ERBB2, we con-
sidered only membranous staining (Figure 1e–h). Scoring was
carried out according to the ASCO/CAP guidelines [27].
We then analyzed the correlations between the levels of
ERBB2, AP-2α, and YY1 proteins in the tumors. Our statistical
analyses showed that ERBB2 expression was significantly
associated with a high AP-2α transcription factor level (p =
0.003) (Table 3). Accordingly, 83% of the tumors with high
AP-2α level had a 2+ or 3+ IHC score for ERBB2 protein and
p53 0.052
Low 46 (84) 36 (78) 10 (22)
High 9 (16) 4 (44) 5 (56)
ER, estrogen receptor; grade, Elston-Ellis modification of Bloom grade; NS, not significant; PR, progesterone receptor.
Table 1 (Continued)
Clinicopathological data of the patients and their relationships with ERBB2 expressionAvailable online http://breast-cancer-research.com/content/10/1/R9
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only 17% had a low ERBB2 expression (0 to 1+). On the other
hand, 83% of the tumors with ERBB2 low expression had a
low level of AP-2α protein. In contrast, no association between
ERBB2 and YY1 expression was observed (Table 3). How-
ever, there was a significant association of ERBB2 protein
level with combined overexpression of AP-2α and YY1 tran-
scription factors (p ≤ 0.02) (Table 3). Indeed, among the 19
cases presenting high levels of both AP-2α and YY1, 84%
Table 2
Sequences of small interfering RNAs and primers for reverse transcription-polymerase chain reaction
Sequence 5'-3' Location
siRNAs
siAP-2α ss CCGAAUUUCCUGCCAAAGCdTdT
siAP-2α as GCUUUGGCAGGAAAUUCGGdTdT
siAP-2γ ss UUAAAUAUUCUGCCACUGGdTdT
siAP-2γ as CCAGUGGCAGAAUAUUUAAdTdT
siYY1 ss GAACUCACCUCCUGAUUAUdTdT
siYY1 as AUAAUCAGGAGGUGAGUUCdTdT
RT-PCR primers
AP-2α forward AGCTGAATTTCTCAACCGACAAC 1,013 (exon 5)
AP-2α reverse TAGCCAGGAGCATGTTTTTTCTT 1,083 (exon 6)
AP-2γ forward CAGAAGAGCCAAATCGAAAAATG 1,041 (exons 5–6)
AP-2γ reverse ATTCAACCCAATCTTGTCCAACTT 1,107 (exon 6)
ERBB2 forward CTGAACTGGTGTATGCAGATTGC 2,617 (exon 20)
ERBB2 reverse TTCCGAGCGGCCAAGTC 2,699 (exon 21)
as, antisense strand; RT-PCR, reverse transcription-polymerase chain reaction; siRNA, small interfering RNA; ss, sense strand.
Figure 1
Detection of activator protein 2 alpha (AP-2α), Yin Yang 1 (YY1), and ERBB2 by immunohistochemistry in breast tumors Detection of activator protein 2 alpha (AP-2α), Yin Yang 1 (YY1), and ERBB2 by immunohistochemistry in breast tumors. (a) Case with low immu-
noreactivity for AP-2α. (b) Tumor sample expressing high level of AP-2α protein in more than 80% of the nuclei.(c) Tumor with low immunoreactivity 
for YY1. (d) Case expressing high level of YY1 protein in more than 80% of the nuclei. (e) Case with no ERBB2 membrane staining, scored as IHC 
0. (f) Tumor with partial weak membrane staining, scored as IHC 1+. (g) Case with ERBB2 score of 2+. (h) Tumor with thick circumferential ERBB2 
membrane staining, scored as IHC 3+.Breast Cancer Research    Vol 10 No 1    Allouche et al.
Page 6 of 11
(page number not for citation purposes)
had an ERBB2 2+ or 3+ score (Table 3).
Levels of both AP-2a and YY1 proteins are inversely 
associated with ERBB2 amplification status in primary 
breast cancer samples
FISH demonstrated ERBB2 gene amplification in 11 cases of
breast cancer. All of these had an ERBB2 3+ score in IHC.
Moreover, out of the 15 ERBB2 3+ cases, 11 were FISH-pos-
itive, 2 showed no ERBB2 amplification, 1 was borderline with
an average of 4 copies of ERBB2 gene per cell, and 1 was
undetermined due to lack of material for FISH testing. Interest-
ingly, the 2 cases of ERBB2 3+ immunostaining without gene
amplification and the borderline case showed high AP-2α and
YY1 levels. On the other hand, all the ERBB2 3+ cases with
low levels of both AP-2α and YY1 showed ERBB2  gene
amplification. Furthermore, when considering the entire
ERBB2 expressing group (1+, 2+, 3+), we observed a signif-
icant inverse correlation between ERBB2 FISH status on one
hand and AP-2α and YY1 levels on the other hand (p = 0.017
and 0.029, respectively) (Table 4). In particular, 80% of the
cases with high levels of both AP-2α and YY1 proteins did not
present  ERBB2  gene amplification (p  = 0.006) (Table 4).
These results suggest that when the ERBB2  gene is not
amplified, the ERBB2 expression may rely partially on AP-2α
and YY1 transcription factor levels. Accordingly, considering
only the FISH-negative cases (n = 34), the correlation
between ERBB2 and AP-2α levels was higher than in the
whole group (r = 0.67, p < 0.001 compared with r = 0.31, p
= 0.022 in the whole group). Interestingly, the percentage of
ERBB2 2+3+/AP-2α-low cases decreased (12% in the FISH-
negative group compared with 24% in the entire group) (Table
5). Similarly, the percentage of ERBB2-positive/AP-2α-low/
YY1-low cases diminished (from 22% in the whole group to
9% in the FISH-negative group) (Table 5). These results indi-
cate that high ERBB2 expression may result either from gene
amplification or from increased transcription factor levels.
Inhibition of AP-2 and YY1 downregulates ERBB2 
expression in vitro
After these correlation results in breast cancer specimens, we
sought to study these relationships on the functional side.
Although the AP-2 family is known to activate the ERBB2 pro-
moter in reporter vectors, the effect of these transcription fac-
tors on the expression of the endogenous ERBB2 gene has
not been clearly established. To find out whether AP-2 factors
do contribute functionally to ERBB2 overexpression in vivo,
we measured ERBB2 mRNA levels in breast cancer cells in
which the expressions of AP-2α and AP-2γ were downregu-
lated by siRNAs. BT-474 breast cancer cells overexpressing
ERBB2, both through amplification and enhanced transcrip-
tion, were transfected with AP-2α and AP-2γ siRNAs, both
independently and in combination for several days. Two differ-
ent siRNAs against AP-2α and three distinct siRNAs against
AP-2γ were first tested (data not shown). The best one for
each target, as tested by Western blotting, was further used in
the study. First, AP-2α and AP-2γ transcript levels were quan-
tified by real-time RT-PCR in the cells transfected by the AP-2
siRNAs and reported to transfection of a control siRNA. Trans-
fection of AP-2α siRNA alone inhibited AP-2α expression (Fig-
ure 2a) but did not modify the AP-2γ transcript level (Figure
2b). Comparable results were obtained in cells transfected
with AP-2γ siRNA alone (Figure 2a,b). Moreover, transfection
of both AP-2α and AP-2γ siRNAs induced a decrease in both
mRNA levels (Figure 2a,b). Similar results were obtained at the
Table 3
Associations between ERBB2 and AP-2α and/or YY1 levels determined by immunohistochemistry
ERBB2 expression (percentage)
n 0/1+ 2+ 3+ P value
AP-2α expression 0.003
Low 32 19 (59) 5 (16) 8 (25)
High 23 4 (17) 12 (52) 7 (31)
YY1 expression 0.318
Low 30 15 (50) 7 (23) 8 (27)
High 25 8 (32) 10 (40) 7 (28)
Combination 0.016
AP-2α lo/YY1 lo 26 14 (54) 4 (15) 8 (31)
AP-2α lo/YY1 hi or AP-2α hi/YY1 lo 10 6 (60) 4 (40) 0 (0)
AP-2α hi/YY1 hi 19 3 (16) 9 (47) 7 (37)
AP-2α, activator protein 2 alpha; hi, high expression; lo, low expression; YY1, Yin Yang 1.Available online http://breast-cancer-research.com/content/10/1/R9
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protein level (Figure 2c, Western blotting). Markedly, 3 days
after treatment with the combination of AP-2α and AP-2γ siR-
NAs, both factors were undetectable (Figure 2c, lane 4), dem-
onstrating that the siRNAs specifically inhibited the expression
of their targets. We then quantified ERBB2 transcript level by
real-time RT-PCR in those cells transfected by the siRNAs.
Either the AP-2α siRNA or the AP-2γ siRNA alone produced a
small transient downregulation of the ERBB2 transcript level
(Figure 2d). Interestingly, transfection of both AP-2α and AP-
2γ siRNAs induced a significant decrease in the endogenous
ERBB2 mRNA level (Figure 2d). This result was also obtained
with another set of siRNAs against AP-2α and AP-2γ (data not
shown). Moreover, the inhibition was seen at the protein level
(Figure 2e, lane 2). Indeed, we observed a reduction of
ERBB2 protein level to 57% of control upon transfection of
both siRNAs directed against AP-2α and AP-2γ. Going
deeper, we further added an siRNA directed against YY1 and
observed that the ERBB2 protein level could be decreased
even further to 22% of control by this combination of siRNAs
(Figure 2e, lane 4). These results are strong evidence that AP-
2 and YY1 transcription factors effectively participate in
ERBB2 expression in breast cancer cells.
AP-2 and YY1 protein levels are correlated both in 
mammary cancer cell line and tissue specimens
Surprisingly, we also observed a strong association between
AP-2α and YY1 expression levels in the primary breast tumors
(p < 0.001) (Table 6). Indeed, the majority of the tumors con-
tained either low levels (26 cases) or high amounts (19 cases)
of both proteins. In contrast, there were only 10 cases (18%)
with a high level of either AP-2α or YY1 alone (Table 6). Next,
we analyzed the relationship between these factors in a breast
cancer cell line. We observed that transfection of an siRNA
directed against YY1 reduced both AP-2α and AP-2γ protein
levels (Figure 2e, lane 3). Additionally, the combination of siR-
NAs directed against both AP-2α and AP-2γ also diminished
the YY1 protein level (Figure 2e, lane 2). These results sug-
gest that, besides the cooperation between AP-2 and YY1
transcription factors on the ERBB2 promoter, there is an intri-
cate relationship between the expressions of these proteins.
Discussion
Multiple in vitro and in vivo data have demonstrated a link
between AP-2 transcription factors and the ERBB2  onco-
gene. The goals of this study were to characterize better the
relationship between the overexpressions of ERBB2 and AP-
2α in primary breast tumors and to analyze the implication of
the YY1 protein as a cofactor of AP-2. Although the number of
tumors analyzed in this study was quite small, it should be
stressed that our observations in tissue samples were further
corroborated by data from the functional in vitro experiments.
Previous immunohistochemical studies on AP-2 and ERBB2
expression in primary breast tumors have reported controver-
sial conclusions [26,29-31]. Indeed, whereas three studies
showed a direct correlation between the levels of one or two
AP-2 transcription factor family members and ERBB2 gene
expression [26,29,31], a fourth one revealed no correlation
[30]. Moreover, Turner and colleagues [31] showed that the
combination of AP-2α and AP-2γ expressions correlated to
ERBB2 expression. It should be noted that these multiple
studies used different antibodies which sometimes did not dis-
criminate between the diverse members of the AP-2 family. In
the present study, we focused on the AP-2α member and
Table 4
Inverse associations between FISH results and AP-2α and/or YY1 levels in ERBB2 expressing group (1+, 2+, 3+)
ERBB2 FISH (percentage)
n Negative Positive P value
AP-2α expression 0.017
Low 12 4 (33) 8 (67)
High 18 15 (83) 3 (17)
YY1 expression 0.029
Low 14 6 (43) 8 (57)
High 16 13 (81) 3 (19)
Combination 0.006
AP-2α lo/YY1 lo 11 3 (27) 8 (73)
AP-2α lo/YY1 hi or AP-2α hi/YY1 lo 4 4 (100) 0 (0)
AP-2α hi/YY1 hi 15 12 (80) 3 (20)
AP-2α, activator protein 2 alpha; FISH, fluorescent in situ hybridization; hi, high expression; lo, low expression; YY1, Yin Yang 1.Breast Cancer Research    Vol 10 No 1    Allouche et al.
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showed a strongly significant correlation between AP-2α and
ERBB2 protein levels. Moreover, we demonstrated that
ERBB2  endogenous expression is inhibited by the
downregulation of both AP-2α and AP-2γ in a breast cancer
cell line. These results and the fact that AP-2 factors bind the
endogenous ERBB2 gene promoter [13,16] strongly suggest
that AP-2 factors do effectively contribute to ERBB2 overex-
pression in breast cancer cells. Our siRNA results further indi-
cate that both AP-2α and AP-2γ are required for ERBB2
overexpression, as already suggested in a study on breast
cancer tissues by Turner and colleagues [31].
In the present study, ERBB2 expression was also associated
with combined high levels of AP-2α and its partner YY1 both
in primary breast tumors, markedly in the absence of ERBB2
gene amplification, and in a breast cancer cell line. The fact
that YY1 needs AP-2 to be recruited on the endogenous
ERBB2 proximal promoter [16] could explain why no direct
relationship between YY1 and ERBB2 levels was seen in the
tumors and highlights the importance of the combination of
high levels of AP-2α and YY1 for ERBB2 expression. To the
best of our knowledge, our study is the first to report both data
in primary tumors and functional results on breast cancer cells
regarding the role of AP-2α transcription factor and one of its
cofactors on ERBB2 gene expression. Further investigations,
however, are needed to determine whether breast tumors with
ERBB2 2+ or 3+ IHC score without gene amplification but
with high levels of AP-2α and YY1 have a particular behaviour
regarding clinical outcome and response to Herceptin
treatment.
Recently, Li and colleagues [32] proposed that AP-2α overex-
pression in breast cancer cells is the consequence of a stabi-
lization of the protein resulting from a defective proteasomal
degradation, leading to an increased ERBB2 gene expres-
sion. Our results further suggest that ERBB2 overexpression
in breast tumors results not only from a high expression of AP-
2α but also from the concomitant high expression of YY1.
Indeed, we have previously shown that YY1 is able to enhance
AP-2α, AP-2β, and AP-2γ transcriptional activity in vitro and
that it is recruited via AP-2 to the ERBB2 endogenous pro-
moter in a breast cancer cell line [16]. Moreover, in the present
study, we observed a strong correlation between AP-2α and
YY1 protein levels in the primary breast tumors and a decrease
in the AP-2α and AP-2γ levels following transfection of an
siRNA targeting YY1. These data suggest that there may be a
two-sided contribution of YY1 for ERBB2 expression. On the
one hand, YY1 increases the AP-2α and AP-2γ protein levels,
and on the other hand, YY1 stimulates AP-2α and AP-2γ tran-
scriptional activity. This view fits well with the additive effect of
the siRNAs targeting AP-2α, AP-2γ, and YY1 for inhibiting
ERBB2 endogenous level.
Another finding of this study was the positive correlation
between AP-2α and YY1. Interestingly, AP-2α promoter is
dependent upon an initiator element for proper transcription,
and we noticed a potential YY1 binding site at the transcrip-
tion start site of the AP-2α gene (position +4) [33]. Since YY1
can act as an initiator factor [24], this could explain the effect
of YY1 siRNA on the AP-2α level. We also found a perfect AP-
2 consensus binding site on the YY1 promoter at -236 base
pairs upstream from the transcription start site [34]. Further
studies are needed to determine whether these binding sites
Table 5
Associations between ERBB2 and AP-2α and/or YY1 levels (immunohistochemistry) in the FISH-negative group
ERBB2 expression (percentage)
n 0/1+ 2+ 3+ P value
AP-2α expression <0.001
Low 18 14 (78) 4 (22) 0 (0)
High 16 2 (12) 11 (69) 3 (19)
YY1 expression 0.106
Low 16 10 (63) 6 (37) 0 (0)
High 18 6 (33) 9 (50) 3 (17)
Combination 0.015
AP-2α lo/YY1 lo 13 10 (77) 3 (23) 0 (0)
AP-2α lo/YY1 hi or AP-2α hi/YY1 lo 8 4 (50) 4 (50) 0 (0)
AP-2α hi/YY1 hi 13 2 (15) 8 (62) 3 (23)
AP-2α, activator protein 2 alpha; FISH, fluorescent in situ hybridization; hi, high expression; lo, low expression; YY1, Yin Yang 1.Available online http://breast-cancer-research.com/content/10/1/R9
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are functional and may explain the relationship between AP-2α
and YY1 levels.
Conclusion
We demonstrated, for the first time, the implication of AP-2α
in combination with its cofactor, YY1, in ERBB2 oncogene
overexpression in breast tumors both in vitro and in breast
cancer tissue specimens. Moreover, we showed that at least
two mechanisms can lead to pathological ERBB2 overexpres-
sion in breast cancer: ERBB2  gene amplification and
increased transcription through high levels of transcriptional
activators, such as AP-2α and YY1. We hope that these data
open a new way in the research field of ERBB2 overexpres-
sion and its pathogenic role in breast tumors.
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